Epidemiology of hepatocellular carcinoma in Japan

被引:166
作者
Umemura, Takeji [1 ]
Ichijo, Tetsuya [1 ]
Yoshizawa, Kaname [1 ]
Tanaka, Eiji [1 ]
Kiyosawa, Kendo [2 ]
机构
[1] Shinshu Univ, Sch Med, Dept Internal Med, Div Gastroenterol & Hepatol, Matsumoto, Nagano 3908621, Japan
[2] Nagano Red Cross Hosp, Nagano, Japan
关键词
HCC; HCV; HBV; nonalcoholic steatohepatitis (NASH); interferon; CHRONIC HEPATITIS-C; PRIMARY LIVER-CANCER; B-VIRUS GENOTYPES; FOLLOW-UP SURVEY; INTERFERON THERAPY; RISK;
D O I
10.1007/s00535-008-2251-0
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Primary liver cancer, 95% of which is hepatocellular carcinoma (HCC), is ranked third in men and fifth in women as a cause of death from malignant neoplasms in Japan. The number of deaths and death rate of HCC began to increase sharply in 1975. These numbers peaked at 34 510 and 27.4/100 000, respectively, in 2004, but decreased to 33 662 annual deaths and a 26.7/100 000 death rate in 2006. Although hepatitis B virus (HBV) and hepatitis C virus (HCV) infection are both major causes of HCC, HCV-related HCC represents 70% of all cases. The incidence of HCC without hepatitis B surface antigen (HBsAg) or antibodies to HCV (anti-HCV) accounts for 8%-15% of HCC patients nationwide. Geographically, HCC is more frequent in western than eastern Japan, and death rates of HCC in each prefecture correlate with anti-HCV, but not HBsAg, prevalence. Interferon therapy for chronic hepatitis C reduces the risk of development of HCC, especially among patients with sustained virological response. Further research should focus on the mechanisms of carcinogenesis by HCV and HBV, development of more effective treatments, and establishment of early detection and preventative approaches. Better understanding of HCC unrelated to HCV and HBV, possibly caused by steatohepatitis and diabetes, should also be a major concern in future studies.
引用
收藏
页码:102 / 107
页数:6
相关论文
共 17 条
[1]   Report of the 16th follow-up survey of primary liver cancer [J].
Ikai, I ;
Arii, S ;
Ichida, T ;
Okita, K ;
Omata, M ;
Kojiro, M ;
Takayasu, K ;
Nakanuma, Y ;
Makuuchi, M ;
Matsuyama, Y ;
Yamaoka, Y .
HEPATOLOGY RESEARCH, 2005, 32 (03) :163-172
[2]   Report of the 17th Nationwide Follow-up Survey of Primary Liver Cancer in Japan [J].
Ikai, Iwao ;
Arii, Shigeki ;
Okazaki, Masatoshi ;
Okita, Kiwamu ;
Omata, Masao ;
Kojiro, Masamichi ;
Takayasu, Kenichi ;
Nakanuma, Yasuni ;
Makuuchi, Masatoshi ;
Matsuyama, Yutaka ;
Monden, Morito ;
Kudo, Masatoshi .
HEPATOLOGY RESEARCH, 2007, 37 (09) :676-691
[3]   Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: A long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis [J].
Ikeda, K ;
Saitoh, S ;
Arase, Y ;
Chayama, K ;
Suzuki, Y ;
Kobayashi, M ;
Tsubota, A ;
Kobayashi, M ;
Nakamura, I ;
Murashima, N ;
Kumada, H ;
Kawanishi, M .
HEPATOLOGY, 1999, 29 (04) :1124-1130
[4]   Antibody to hepatitis B core antigen and risk for hepatitis C-related hepatocellular carcinoma: A prospective study [J].
Ikeda, Kazuki ;
Marusawa, Hiroyuki ;
Osaki, Yukio ;
Nakamura, Takefumi ;
Kitajima, Naoto ;
Yamashita, Yukitaka ;
Kudo, Masatoshi ;
Sato, Tosiya ;
Chiba, Tsutomu .
ANNALS OF INTERNAL MEDICINE, 2007, 146 (09) :649-656
[5]   Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C [J].
Imai, Y ;
Kawata, S ;
Tamura, S ;
Yabuuchi, I ;
Noda, S ;
Inada, M ;
Maeda, Y ;
Shirai, Y ;
Fukuzaki, T ;
Kaji, I ;
Ishikawa, H ;
Matsuda, Y ;
Nishikawa, M ;
Seki, K ;
Matsuzawa, Y .
ANNALS OF INTERNAL MEDICINE, 1998, 129 (02) :94-99
[6]  
*JAP LCSGI, 2000, KANZO, V41, P799
[7]  
*JAP LCSGI, 1999, KANZO, V40, P288
[8]  
*JAP LCSGI, 1997, KANZO, V38, P317
[9]  
*JAP LCSGI, 2003, KANZO, V44, P157
[10]   Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C [J].
Kasahara, A ;
Hayashi, N ;
Mochizuki, K ;
Takayanagi, M ;
Yoshioka, K ;
Kakumu, S ;
Iijima, A ;
Urushihara, A ;
Kiyosawa, K ;
Okuda, M ;
Hino, K ;
Okita, K .
HEPATOLOGY, 1998, 27 (05) :1394-1402